Roche has said its oral BTK inhibitor fenebrutinib could become the first drug in the class to be approved for multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results